Ovarian Clear Cell Carcinoma Clinical Trial
Official title:
A Multicentre Phase II Randomised Trial of Durvalumab (MEDI4736) Versus Physician's Choice Chemotherapy in Recurrent Ovarian Clear Cell Adenocarcinomas (MOCCA)
The purpose of this study is to find out if treatment with a study drug, durvalumab has beneficial effects in people who have recurrent ovarian clear cell cancer and to determine what effects (both good and bad) it has on them and their cancer.
The purpose of this study is to find out if treatment with a study drug, durvalumab has
beneficial effects in patients who have recurrent ovarian clear cell cancer and to determine
what effects (both good and bad) it has on them and their cancer.
In the recurrent ovarian clear cell cancer (OCCC) setting, responses to further lines of
chemotherapy are uniformly low. Given the limited benefit observed from chemotherapy
treatments, there is now great interest in the development of molecular targeted therapy for
the treatment of OCCC, including immunotherapy.
Researchers have found that sometimes the body's own immune system may be able to slow down
or control cancer growth. Sometimes though, this natural immune system response stops, and
the cancer cells are not killed by the immune system. Research has shown that in some
patients, proteins on the surface of cancer cells and immune cells bind together and send
signals that stop the immune cells from killing the cancer cells. One such protein is called
Programmed Cell Death Ligand 1 or PD-L1 for short. New drugs like durvalumab work to block
this signal and to increase the immune response against cancer cells. Durvalumab is an
antibody to PDL1 (a protein that binds to PD1 and blocks the anti tumour activity of immune
cells), and it is hoped that by blocking the interaction between PDL1 and PD1, the immune
cells will once again be able to attack the cancer cells and thus prevent or slow down cancer
growth.
This will be the first study to evaluate the efficacy of durvalumab in patients with
recurrent ovarian clear cell carcinomas.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05415098 -
Study of Safety, Pharmacokinetic and Efficacy of APG-5918 in Advanced Solid Tumors or Lymphomas
|
Phase 1 | |
| Recruiting |
NCT05296512 -
Pembrolizumab and Lenvatinib in Clear Cell Ovarian Cancer
|
Phase 2 | |
| Completed |
NCT01914510 -
A Study of ENMD-2076 in Ovarian Clear Cell Cancers
|
Phase 2 | |
| Recruiting |
NCT04104776 -
A Study of CPI-0209 in Patients With Advanced Solid Tumors and Lymphomas
|
Phase 1/Phase 2 | |
| Completed |
NCT03297424 -
A Study of PLX2853 in Advanced Malignancies.
|
Phase 1 | |
| Not yet recruiting |
NCT05600998 -
A Study of Camrelizumab in Combination With Anlotinib in Subjects Advanced Ovarian Clear Cell Carcinoma
|
N/A | |
| Recruiting |
NCT06065462 -
Safety and Efficacy of Targeting PP2A in Ovarian Clear Cell Carcinoma Using Dostarlimab and LB-100
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05099978 -
Asian Multicenter Prospective Study of ctDNA Sequencing
|
||
| Not yet recruiting |
NCT05759312 -
Zimberelimab Plus Metformin for Recurrent Ovarian Clear Cell Carcinoma
|
Phase 1/Phase 2 | |
| Not yet recruiting |
NCT06279104 -
A Comparative Study of the Treatment of Real-world Patients With Clear Cell Carcinoma of the Ovary
|
||
| Terminated |
NCT02837991 -
A Dose Escalation, Safety and Activity Study of CDX-014 in Patients With Renal Cell Carcinoma and Ovarian Clear Cell Carcinoma
|
Phase 1 | |
| Recruiting |
NCT05498597 -
AMT-151 in Patients With Selected Advanced Solid Tumours
|
Phase 1 | |
| Recruiting |
NCT05226507 -
A Phase 1 Clinical Study of NXP800 in Subjects With Advanced Cancers and Expansion in Subjects With Ovarian Cancer
|
Phase 1 | |
| Recruiting |
NCT05281471 -
Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)
|
Phase 3 | |
| Recruiting |
NCT04735861 -
Sintilimab Plus Bevacizumab in Recurrent/Persistent Ovarian Clear Cell Carcinoma
|
Phase 2 | |
| Recruiting |
NCT02866370 -
Study Of Nintedanib Compared To Chemotherapy in Patients With Recurrent Clear Cell Carcinoma Of The Ovary Or Endometrium
|
Phase 2 |